Latest Ratios: P/E Ratio -3.1x · EV/EBITDA N/A · ROE -86.2%. (2014–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $45M | $38M | $243M | $148M | $4M | $40M | $22M | $5M | $18M | $16M | — |
| Enterprise Value | $50M | $43M | $227M | $142M | $-1185949 | $25M | $10M | $3M | $11M | $3M | — |
| P/E Ratio → | -3.14 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.10 | 0.93 | 7.47 | 7.68 | 0.23 | 2.88 | 2.96 | 1.30 | 7.25 | 10.39 | — |
| P/B Ratio | 4.26 | 3.34 | 9.84 | 16.44 | 0.57 | 2.59 | 1.94 | 2.74 | 2.76 | 1.30 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.06 | 6.97 | 7.36 | -0.08 | 1.81 | 1.36 | 0.83 | 4.57 | 2.07 | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 65.7% | 65.7% | 71.2% | 68.5% | 65.9% | 74.4% | 65.7% | 76.1% | 70.2% | 67.6% | 74.4% |
| Operating Margin | -35.2% | -35.2% | -19.1% | -42.8% | -68.6% | -74.1% | -138.5% | -281.3% | -430.8% | -420.1% | -296.8% |
| Net Profit Margin | -38.1% | -38.1% | -19.0% | -42.3% | -68.9% | -74.9% | -152.5% | -279.1% | -422.1% | -776.0% | -327.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -86.2% | -86.2% | -36.7% | -106.2% | -98.5% | -76.9% | -172.7% | -259.7% | -109.3% | -97.2% | — |
| ROA | -38.5% | -38.5% | -21.8% | -65.9% | -70.9% | -59.6% | -108.5% | -144.0% | -92.7% | -154.8% | -228.4% |
| ROIC | -86.1% | -86.1% | -83.4% | -288.0% | -732.0% | -13130.0% | — | — | — | — | — |
| ROCE | -46.2% | -46.2% | -30.1% | -105.1% | -95.4% | -74.3% | -144.3% | -236.2% | -111.3% | -117.5% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.70 | 1.70 | 0.33 | 0.07 | 0.09 | 0.05 | 0.01 | 1.45 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.46 | -0.66 | -0.70 | -0.75 | -0.96 | -1.04 | -0.99 | -1.02 | -1.04 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -15.52 | -15.52 | — | — | — | — | -23.36 | -95.00 | -29.33 | -18.24 | -9.58 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.30 | 3.30 | 3.22 | 2.49 | 2.56 | 4.46 | 5.03 | 1.58 | 4.24 | 9.32 | 0.38 |
| Quick Ratio | 2.93 | 2.93 | 2.91 | 2.16 | 2.17 | 4.27 | 4.79 | 1.47 | 4.11 | 9.19 | 0.35 |
| Cash Ratio | 2.20 | 2.20 | 2.44 | 1.62 | 1.48 | 3.62 | 4.27 | 1.15 | 3.52 | 8.73 | 0.27 |
| Asset Turnover | — | 1.06 | 0.77 | 1.32 | 1.53 | 0.69 | 0.52 | 0.58 | 0.30 | 0.11 | 0.67 |
| Inventory Turnover | 4.50 | 4.50 | 2.96 | 3.36 | 3.79 | 4.38 | 3.68 | 2.09 | 2.84 | 2.51 | 3.42 |
| Days Sales Outstanding | — | 36.53 | 42.89 | 45.20 | 44.49 | 51.63 | 44.52 | 40.35 | 57.09 | 69.55 | 37.88 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.4% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.4% | 0.0% | — |
| Shares Outstanding | — | $42M | $38M | $29M | $7M | $6M | $3M | $553787 | $410152 | $143927 | $6M |
Liquidity and cash depletion
Based on reported figures, Myomo trades at a P/S multiple of 1.02, which appears to discount the company's growth potential significantly compared to historical norms and suggests that the market is pricing in substantial execution risk regarding the transition to sustainable, profitable insurance-reimbursed revenue streams.
The current valuation multiple implies that investors are prioritizing the company's immediate liquidity constraints over its long-term technological moat. Given the lack of positive earnings or free cash flow, traditional P/E or EV/EBITDA metrics are non-informative, leaving the P/S ratio as the primary, albeit limited, gauge of market sentiment.
As reported in financial statements, Myomo's ROIC has remained consistently negative, bottoming out at -67.3% in 2024Q1, which indicates that the company is currently destroying shareholder value rather than compounding it as it attempts to scale its specialized orthotic device manufacturing and clinical fitting infrastructure.
The persistent negative returns on invested capital suggest that the company's high fixed-cost base, particularly in patient advocacy and reimbursement navigation, is not yet being offset by sufficient unit volume. Investors should monitor whether future capital allocation shifts toward manufacturing automation, which may eventually improve the efficiency of the return profile.
According to recent SEC filings, Myomo's cash conversion cycle has fluctuated significantly, reaching 87 days in 2026Q1, which highlights the inherent friction in the company's reimbursement-heavy business model and the resulting difficulty in converting device sales into timely, predictable cash inflows for operational support.
The elevated days inventory outstanding (DIO) and days sales outstanding (DSO) suggest that the company is carrying significant working capital burdens that tie up precious liquidity. This inefficiency appears structural, as the reliance on third-party insurance authorizations creates a bottleneck that prevents the company from achieving a leaner, more responsive operational cycle.
Based on Myomo's reported figures, the debt-to-equity ratio has surged to 2.11 as of 2026Q1, marking a concerning shift toward debt-funded operations that may limit the company's strategic flexibility and increase its vulnerability to interest rate volatility in an already capital-constrained environment.
The rapid increase in leverage, coupled with negative interest coverage, suggests that the company is increasingly reliant on external financing to bridge its operational gaps. This trend warrants further investigation, as it may signal a transition toward a more precarious capital structure that could necessitate further dilutive equity raises.
The market commonly misapplies standard robotics valuation multiples to Myomo, which obscures the company's true nature as a specialized insurance navigation and clinical data firm rather than a high-volume hardware manufacturer, leading to potential mispricing of its long-term strategic value and competitive moat.
By focusing on unit sales and hardware-centric multiples, analysts may overlook the value of the company's proprietary EMG signal-processing database and its institutional expertise in navigating complex reimbursement codes. A more appropriate framework would involve valuing the company based on its potential as a 'toll-bridge' provider of clinical data and software licensing, rather than just a device vendor.
Includes 30+ ratios · 12 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MYO stock.
Myomo, Inc.'s current P/E ratio is -3.1x. This places it at the 50th percentile of its historical range.
Myomo, Inc.'s return on equity (ROE) is -86.2%. The historical average is -153.9%.
Based on historical data, Myomo, Inc. is trading at a P/E of -3.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Myomo, Inc. has 65.7% gross margin and -35.2% operating margin.